TY - JOUR T1 - GINA 2019：在哮喘管理JF根本性的变化 - 欧洲呼吸杂志JO - 欧洲呼吸j执行 - 10.1183 / 13993003.01046-2019 VL - 53 - 6 SP - 1901046 AU - Reddel，海伦K. AU - 杰拉德，J.马克AU - 贝特曼，埃里克D. AU - Bacharier，伦纳德B. AU - 贝克尔，艾伦AU - Brusselle，盖伊AU - 布尔，罗兰AU - 克鲁兹，阿尔瓦罗A. AU - 弗莱明，路易斯AU - 井上，弘正AU - 柯，范妮围山盟 - 克里希南，杰里A. AU - 利维，马克L. AU - 林，江涛AU - 彼得森，索伦E. AU - 谢赫，阿齐兹AU - Yorgancioglu，阿尔苏AU - 博利特，Louis-菲利普Y1 - 2019年6月1日UR - //www.qdcxjkg.com/content/53/6/1901046.abstract N2 - 四月2019年公布的全球哮喘（GINA）（专栏1）新建议that might be considered the most fundamental change in asthma management in 30 years. The new recommendations follow a decade-long programme of work by GINA, prompted by concerns about the risks and consequences of the long-standing approach of commencing asthma treatment with short-acting β2-agonists (SABA) alone. These initiatives were aimed at obtaining evidence about effective treatment options for mild asthma and providing consistent messaging for patients and clinicians across the spectrum of asthma severity.GINA no longer recommends treating adults/adolescents with asthma with short-acting bronchodilators alone. Instead, they should receive symptom-driven (in mild asthma) or a daily corticosteroid-containing inhaler, to reduce risk of severe exacerbations. http://bit.ly/310LLzEThe authors acknowledge with respect and gratitude the tireless work of Claude Lenfant and Suzanne Hurd for GINA, from its establishment in 1993 until their retirement in 2014, and of Rebecca Decker, the Global Program Director for GINA, since 2014. The authors are members of the GINA Science Committee and/or the GINA Board. Louis-Philippe Boulet is Chair of the GINA Board; Helen K. Reddel is Chair of the GINA Science Committee; and Mark L. Levy is Chair of the GINA Dissemination and Implementation Committee. ER -